NASDAQ:FHTX - Foghorn Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 43.51 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.42
▲ +0.71 (4.25%)
1 month | 3 months | 12 months
Get New Foghorn Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FHTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FHTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +43.51% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Foghorn Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $27.00 and a low forecast of $24.00. The average price target represents a 43.51% upside from the last price of $17.42.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Foghorn Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020Morgan StanleyInitiated CoverageOverweight$24.00High
i
11/17/2020WedbushInitiated CoverageOutperform$24.00High
i
Rating by R. Driscoll at Wedbush
11/17/2020CowenInitiated CoverageOutperformHigh
i
11/17/2020The Goldman Sachs GroupInitiated CoverageBuy$27.00High
i
(Data available from 11/25/2015 forward)
Foghorn Therapeutics logo
Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $17.42
$16.49
$17.90

50 Day Range

MA: N/A

52 Week Range

Now: $17.42
$14.03
$20.30

Volume

97,151 shs

Average Volume

188,580 shs

Market Capitalization

$621.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A